Special Issue "Recent Advances in Carcinogenesis Transcription Factors: Biomarkers and Targeted Therapies"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 7612
Special Issue Editors
Interests: carcinogenesis; chemoprevention; transcription factors; cancer biomarkers; drug resistance
Interests: stem cells and cancer; keratinocyte stem cells; bone marrow stem cells; epithelial cancers
Interests: targeted therapy; cancer biology; biomarkers; chemoprevention; molecular biology
Special Issue Information
Dear Colleagues,
Recent Advances in Carcinogenesis Transcription Factors: Biomarkers and Targeted Therapies──How and when does a good cell go bad?
When a carcinogen-initiated cell goes bad, traditionally, the dogma is that it requires both a carcinogen and a tumor promoter. However, many cells are exposed to both agents but do not become cancerous. The transformation is believed to require a mutation or activation of a favorite oncogene but is also known to require a non-normal cell proliferation event or at least something beyond the normal day-to-day cell turnover. This “induced” proliferation event changes the entire phenotype of the initiated cell including the RNA and subsequent translated proteins. However, non-cancerous cells are not necessarily affected. Thus, transcription factors appear to be a major link between the mutation being established in subsequent rounds of cell cycle and the expression of the cancer phenotype. This Special Issue focuses on mutations in specific transcription factors that are considered to be most important in leading a bad cell to progress to cancer. This should include the coordinate regulation of cellular and tissue processes such as inflammation, hypoxia, and cell cycle/differentiation from a transcriptional point of view, as well as their regulation and coordination by enhancers and super enhancers and how they act as oncogenic drivers. Articles could also include how researchers jumped over the hurdle of determining how transcription factors could be druggable targets, which was proposed years ago, but not achieved until relatively recently.
Prof. Dr. Ann M. Bode
Prof. Dr. Rebecca Morris
Dr. Tianshun Zhang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transcription factor
- oncogenic driver
- targeted drug design
- coordinate regulation of gene expression
- super enhancers
- carcinogenesis
- targeted therapies
- gene regulation
- biomarkers
